Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.
FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer
Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers
ChatGPT Displays Potential for Genetic Counseling in Gynecologic Oncology
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology
Dr Wang on the Role of Active Surveillance in Patients With Renal Masses
Dr Meeks on Harnessing Innovation in Bladder Cancer
PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer
Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC